Abstract
Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have